Cargando…

The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update

Detalles Bibliográficos
Autores principales:	El-Shater Bosaily, Ahmed, Parker, Christopher, Brown, Louise C., Gabe, Rhian, Hindley, Richard G., Kaplan, Richard, Emberton, Mark, Ahmed, Hashim U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V 2015
Materias:	Clinical Trial Update
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694096/ https://www.ncbi.nlm.nih.gov/pubmed/26839919 http://dx.doi.org/10.1016/j.euf.2015.04.007

Ejemplares similares

PROMIS — Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer()
por: El-Shater Bosaily, A., et al.
Publicado: (2015)

The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial
por: El-Shater Bosaily, A, et al.
Publicado: (2016)

Erratum: The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial
por: El-Shater Bosaily, A, et al.
Publicado: (2016)

Defining the level of evidence for technology adoption in the localized prostate cancer pathway
por: Valerio, Massimo, et al.
Publicado: (2014)

What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort
por: Norris, Joseph M., et al.
Publicado: (2020)

Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial
por: Stavrinides, Vasilis, et al.
Publicado: (2023)

Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer
por: Elliott, Daisy, et al.
Publicado: (2018)

Feasibility of Comparative Health Research Outcome of Novel Surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study
por: Day, Emily, et al.
Publicado: (2021)

False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS [Image: see text] ()
por: Stavrinides, Vasilis, et al.
Publicado: (2021)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS)
por: Faria, Rita, et al.
Publicado: (2018)

Barriers impacting the POINT pragmatic trial: the unavoidable overlap between research and intervention procedures in “real-world” research
por: Dir, Allyson L., et al.
Publicado: (2021)

Improving Patient\Population Health: Using ‘Why’ to Develop a Transformative Research Center
por: Aebersold, Michelle, et al.
Publicado: (2021)

The role of palliative medicine in ICU bed allocation in COVID-19: a joint position statement of the Singapore Hospice Council and the Chapter of Palliative Medicine Physicians
por: Krishna, Lalit Kumar Radha, et al.
Publicado: (2020)

Update in Women’s Health
por: Walsh, Judith M. E., et al.
Publicado: (2009)

Coping with Persistent Pain, Effectiveness Research into Self-management (COPERS): statistical analysis plan for a randomised controlled trial
por: Kahan, Brennan C, et al.
Publicado: (2014)

Design and implementation of the Professional Wellbeing Programme of the Medical Council of Uruguay
por: Dapueto, Juan J., et al.
Publicado: (2023)

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
por: Makker, Vicky, et al.
Publicado: (2023)

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
por: Davies, Andrew J., et al.
Publicado: (2023)

Promoting Recruitment using Information Management Efficiently (PRIME): statistical analysis plan for a stepped wedge cluster randomised trial within the REstart or STop Antithrombotics Randomised Trial (RESTART)
por: Parker, Richard A., et al.
Publicado: (2017)

Hotline sessions presented at the American College of Cardiology Congress 2009
por: Maier, Lars S., et al.
Publicado: (2009)

Update of: Ndiaye et al., High-Risk Advanced Maternal Age and High Parity Pregnancy: Tackling a Neglected Need Through Formative Research and Action
Publicado: (2018)

A scoping review of researchers’ involvement in health policy dialogue in Africa
por: Yimgang, Doris, et al.
Publicado: (2021)

Anaphylaxis: emergency management for health professionals [Update 1]
Publicado: (2022)

The London County Council
Publicado: (1915)

Updates for hyperglycemia in pregnancy: The ongoing journey for maternal–neonatal health
por: Li, Hung‐Yuan, et al.
Publicado: (2022)

Update of: Harvey, Observe Before You Leap: Why Observation Provides Critical Insights for Formative Research and Intervention Design That You'll Never Get From Focus Groups, Interviews, or KAP Surveys
Publicado: (2018)

Treatment of Stable Angina Pectoris With Ivabradine in Everyday Practice: A Pan‐Hellenic, Prospective, Noninterventional Study
por: Zarifis, John, et al.
Publicado: (2015)

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2022)

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
por: Lassman, Andrew B., et al.
Publicado: (2022)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
por: Rugo, Hope S., et al.
Publicado: (2023)

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
por: Laetsch, Theodore W., et al.
Publicado: (2023)

Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study
por: Van Assche, Indra A., et al.
Publicado: (2023)

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
por: Makker, Vicky, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
por: Platzbecker, Uwe, et al.
Publicado: (2022)

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
por: Herbst, Roy S., et al.
Publicado: (2023)

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
por: de Castro, Gilberto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a62jg2it1nmb3tdl09af041q8n